KU 2019 Post San Antonio Breast Cancer Review

 

KU 2019 Post San Antonio Breast Cancer Review
T

SABCS 2019 Updates on Early Stage HR+: Oral Formulation S-1 + Adjuvant ET Improves Outcomes, Younger Women Derive More Benefit from Adjuvant Chemotherapy

By KU 2019 Post San Antonio Breast Cancer Review FEATURING Terry Mamounas
By KU 2019 Post San Antonio Breast Cancer Review FEATURING Terry Mamounas
0 views
March 12, 2020
Comments 0
Login to view comments. Click here to Login

Featured Video

03:57
Lilly Medical Affairs

Resistance Mechanisms to ET, Including ESR1 Mutations in HR+, HER2- …

Feat. K. Jhaveri

Featured Video

06:14
Lilly Medical Affairs

CDK4/6 Inhibitors as First-Line Treatment for HR+, HER2- MBC

Feat. J. O’Shaughnessy
Videos
17:37
KU 2019 Post San Antonio Breast Cancer Review

SABCS 2019 Highlights on Metastatic HER2+ Breast Cancer: Outcomes of…

Feat. W. Gradishar
11:53
KU 2019 Post San Antonio Breast Cancer Review

SABCS 2019 Highlights on Metastatic HER2+ Breast Cancer Management: …

Feat. W. Gradishar
10:29
KU 2019 Post San Antonio Breast Cancer Review

SABCS 2019 Highlights on Adjuvant Therapy Options for HER2+ Breast C…

Feat. W. Gradishar
18:55
KU 2019 Post San Antonio Breast Cancer Review

SABCS 2019 Highlights on Early Stage TNBC: 5-FU Has a Benefit, Neoad…

Feat. V. Kaklamani
06:40
KU 2019 Post San Antonio Breast Cancer Review

SABCS 2019 Highlights on IO in mTNB: IMpassion130 Suggest PD-L1+ Pts…

Feat. V. Kaklamani
09:08
KU 2019 Post San Antonio Breast Cancer Review

SABCS 2019 Updates on Breast Cancer Chemoprevention: Anastrozole Sig…

Feat. T. Mamounas
23:29
KU 2019 Post San Antonio Breast Cancer Review

SABCS 2019 Updates on Early Stage HR+: Oral Formulation S-1 + Adjuva…

Feat. T. Mamounas
07:01
KU 2019 Post San Antonio Breast Cancer Review

SABCS 2019 Updates on Metastatic HR+ BC: PEARL Suggests Treatment Wi…

Feat. T. Mamounas
11:46
KU 2019 Post San Antonio Breast Cancer Review

52 y/o With HER2+/HR- De-novo Metastatic BC / 52 y/o With T2N0 HR+/H…

Feat. A. Kurian, Q. Khan, P. Sharma, V. Kaklamani, T. Mamounas, W. Gradishar
11:23
KU 2019 Post San Antonio Breast Cancer Review

46 y/o F With Grade 2, 2.5 cm, NO ER+ Left BC / 40 y/o Premenopausal…

Feat. A. Kurian, Q. Khan, P. Sharma, V. Kaklamani, T. Mamounas, W. Gradishar
08:39
KU 2019 Post San Antonio Breast Cancer Review

55 y/o Diagnosed With T3NO TNBC / 42 y/o With cT2N+ Grade IlTNBC, Re…

Feat. A. Kurian, Q. Khan, P. Sharma, V. Kaklamani, T. Mamounas, W. Gradishar